Clarus Biologics is Dedicated to the Discovery and Development of Novel Vaccine Technologies
Launched in 2019
Clarus Biologics was launched to increase the availability of safe and effective prophylactic and therapeutic technologies. Its lead product is a next-generation vaccine adjuvant intended to enhance the effectiveness, efficiency and availability of vaccines.
Experienced, Knowledgeable Team
With a management team of biologics industry veterans, experienced microbiologists, and immunologists, Clarus is positioned to capitalize on the current environment and advance rapidly through development.
Accelerated Response Capability
Early integration of R&D and commercial operations, low-cost and small-footprint production, and the versatility of our technology position Clarus for rapid response to future vaccine needs.
The Clarus Management Team has the Experience and Expertise to Deliver
Peter Anderson - President
Peter has spent 23 years working in commercial manufacturing environments within the regulated life sciences industry, progressing from entry level to senior management within mid-size to large companies with global operations (including Wyeth, Novartis and Alcon).
Throughout his career, he has performed quality, validation and regulatory compliance functions supporting new product introductions and routine commercial production. He is co-founder and Principal Consultant of a compliance consulting firm (established in 2013) that helps companies develop and implement cGMP-compliant quality systems; qualify manufacturing facilities; and develop, transfer and validate new production processes.
As an employee and business owner, Peter has experience developing successful teams and has established and demonstrated a thorough understanding of cGMP principles, knowledge of associated global regulatory expectations and industry standards and the ability to critically analyze those expectations in conjunction with relevant scientific thought and business needs to achieve company objectives.
Dr. Robert E. Johnston - CSO, VP of Research & Development
As inventor and developer of the adjuvant, Dr. Johnston provides the technical support necessary to ensure all relevant scientific knowledge is incorporated into development of the pre-clinical, clinical and commercial manufacturing operations and associated critical assays.
During the last 25 years of his career, Dr. Johnston has straddled academic science and entrepreneurial biotechnology. He has devoted his academic life to the study of alphaviruses, the molecular and cell biology of how they replicate and cause disease, and how their characteristics can be utilized to further the creation of vaccines and vaccine technologies.
He has founded or co-founded three biotech companies, all based on discoveries made by himself and the students, postdoctoral fellows, and colleagues who worked in his academic laboratories. He has served in leadership positions, both at UNC (Founding Director of the Carolina Vaccine Institute) and at three companies (CEO, Board Chair, AlphaVax, Inc.; Executive Director, Global Vaccines, Inc; CSO and Vice-President of Research, Clarus Biologics, Inc.).
In addition, over his long career, he has established an extensive network of researchers that can be leveraged to develop key scientific and business collaborations.
Bruno Pancorbo - VP of Process Development
Bruno (Sc.B., Microbiology; Sc.M., Biochemistry) has more than 20 years of experience in biologics drug development (research to Phase III clinical), advancing from entry level to senior management at AlphaVax, Inc. and Medicago, Inc. He has significant experience in development of novel purification methods (protein, virus and nucleic acid); vaccine process development and scale-up; and technology transfer of manufacturing operations and assays.
Bruno has also built departments and developed highly successful teams of development scientists and manufacturing staff. At AlphaVax (a company using another alphavirus-based technology similar to CBI-3A), Bruno developed and optimized many of the same manufacturing processes that will be developed at Clarus Biologics for adjuvant production. Throughout his career, Bruno has proven his ability as a hands-on leader, successfully conducting development work for relevant biologics drug manufacturing processes and building and mentoring teams to do the same.
Michael W. Johnston - General Counsel
Michael W. Johnston is the founding partner of Johnston Legal Group PC. He
graduated with honors from Trinity University and Baylor Law School where he
was an associate editor of the Baylor Law Review.
For over four decades, Mr. Johnston has been a civil litigator focusing on
insurance, consumer, and commercial litigation. In 1997, he was inducted into
the Who’s Who of American Lawyers.
He is a Fellow of the Texas Bar Foundation and member of the State Bar of
Texas, the College of the State Bar of Texas, American Association of Insurance
Consultants and many other law-related organizations. Mr. Johnston is Board
Certified in Civil Trial Law, Consumer and Commercial Law and Civil Pretrial
Practice Advocacy and has earned additional certifications in areas like
arbitration and mediation and received many industry recognitions, including
designation as a Texas “Super Lawyer” beginning in 2005.
Mr. Johnson uses his considerable experience to assist Clarus in the
coordination and formulation of legal strategies; provide advice in areas like risk
management and insurance; and aid in the coordination and execution of public
Explore Clarus Biologics